echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Newly discovered prion therapeutic target

    Newly discovered prion therapeutic target

    • Last Update: 2022-10-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    Prion diseases, such as bovine spongiform encephalopathy ("mad cow disease"), are deadly neurodegenerative infectious diseases that affect humans and other mammals and there is currently no cure


    Prions are altered (i.


    Although a large number of experimental and theoretical studies have been conducted, the molecular mechanisms that regulate the physiological to pathological changes in prion structure from physiological to pathological have not been clear


    Therefore, it is possible to highlight the structure of human prion proteins, which are intermediate products


    Structural and dynamical determinants of a β-sheet-enriched intermediate involved in amyloid fibrillar assembly of human prion protein


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.